Phase 2 study results of Ionis' novel antisense treatment for hereditary angioedema to be presented at ACAAI annual meeting
Go back to Phase 2 study results of Ionis' novel antisense treatment for hereditary angioedema to be presented at ACAAI annual meeting| (NASDAQ: IONS) | Delayed: 44.72 +0.28 (0.63%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $44.44 | 52 Week High | $62.68 | |||
| Open | $44.95 | 52 Week Low | $19.59 | |||
| Day High | $45.25 | P/E | N/A | |||
| Day Low | $44.20 | EPS | $0.00 | |||
| Volume | 2,902,533 | |||||
